Periodic Reporting for period 1 - OABCAP (Demonstration of a new diagnostic device for the Overactive Bladder syndrome)
Reporting period: 2015-03-01 to 2015-08-31
This report describes the results of the feasibility study for the commercialisation of the OABCAP diagnostic device for the Overactive Bladder syndrome.
The feasibility study has been carried out in a working group formed by the consultancy and the company:
• By the consultancy BANTEC GROUP, the members of the team have been the following:
- Senior consultant
- Senior consultant
• By the technology and product owner ALBYN MEDICAL, the members of the team have been the following:
- General Manager
- Administration manager
Five face-to-face meetings have been carried out with specific themes:
1. Feasibility study launch – March 2014
2. Market – March 2014
3. Value proposition, business model and commercialisation – May 2015
4. Costs, revenues and funding scheme – June 2015
5. Results validation – August 2015
The feasibility study has been carried out in a working group formed by the consultancy and the company:
• By the consultancy BANTEC GROUP, the members of the team have been the following:
- Senior consultant
- Senior consultant
• By the technology and product owner ALBYN MEDICAL, the members of the team have been the following:
- General Manager
- Administration manager
Five face-to-face meetings have been carried out with specific themes:
1. Feasibility study launch – March 2014
2. Market – March 2014
3. Value proposition, business model and commercialisation – May 2015
4. Costs, revenues and funding scheme – June 2015
5. Results validation – August 2015
Performed actions within the feasibility study are summarized in the following points:
• Market: The related market to the new product has been analysed and its volume forecast for 2020 has been determined.
• Opportunity: The opportunity of OABCAP in the current urologic equipment and disposables market has been analysed.
• Competition: The characteristics of the competitors’ products have been analysed taking as reference the ALBYN MEDICAL new product.
• Regulatory risk: The regulatory risks have been analysed for each significant market.
• Added value: The OABCAP added value has been established taking into account the current market solutions and their limitations.
• Intellectual property: The freedom to operate analysis has been reviewed to establish the up-to-date status of the protection.
• Business model: Current business model in the market have been analysed and the optimum business model for the commercialisation of the new product has been established.
• Commercialisation: A commercialisation strategy has been established.
• Risks: Main technical and regulatory risks have been determined and specific contingency plans have been defined.
• Resources: Manufacture and sale resources for the commercialisation of the new product have been identified.
• Return on the investment: Sales projections hypothesis, cost structure and the revenue model have been established. The return on the investment has been analysed and the business feasibility has been confirmed.
• Market: The related market to the new product has been analysed and its volume forecast for 2020 has been determined.
• Opportunity: The opportunity of OABCAP in the current urologic equipment and disposables market has been analysed.
• Competition: The characteristics of the competitors’ products have been analysed taking as reference the ALBYN MEDICAL new product.
• Regulatory risk: The regulatory risks have been analysed for each significant market.
• Added value: The OABCAP added value has been established taking into account the current market solutions and their limitations.
• Intellectual property: The freedom to operate analysis has been reviewed to establish the up-to-date status of the protection.
• Business model: Current business model in the market have been analysed and the optimum business model for the commercialisation of the new product has been established.
• Commercialisation: A commercialisation strategy has been established.
• Risks: Main technical and regulatory risks have been determined and specific contingency plans have been defined.
• Resources: Manufacture and sale resources for the commercialisation of the new product have been identified.
• Return on the investment: Sales projections hypothesis, cost structure and the revenue model have been established. The return on the investment has been analysed and the business feasibility has been confirmed.
The new diagnostic device:
• Will determine with high reliability if the patient suffers Overactive Bladder syndrome.
• Will highly decrease the impact of the test in the patient (discomfort).
Thanks to the new diagnostic device a reliable diagnostic evaluation is obtained and thus high treatment costs of the over-diagnosis are avoided improving the sustainability of the European Health and Care systems.
Based on the feasibility study carried out, the business feasibility can be ensured.
• Will determine with high reliability if the patient suffers Overactive Bladder syndrome.
• Will highly decrease the impact of the test in the patient (discomfort).
Thanks to the new diagnostic device a reliable diagnostic evaluation is obtained and thus high treatment costs of the over-diagnosis are avoided improving the sustainability of the European Health and Care systems.
Based on the feasibility study carried out, the business feasibility can be ensured.